MammaPrint regulatory update

Agendia said updated clinical practice guidelines published in the Annals of Oncology confirmed that its MammaPrint "significantly" augments prognostic and predictive information in making key cancer treatment decisions. The European Society of Medical Oncology (ESMO), the Japanese Society of Medical Oncology (JSMO) and the St. Gallen International Breast Cancer Conference Expert Panel provided the guidelines. Agendia markets MammaPrint, which uses a 70-gene signature chip, to assess the risk of breast cancer recurrence. ...